Compare Apartment Investment and Management Co (AIV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apartment Investment and Management Co vs TG Therapeutics Inc — how do they compare? Apartment Investment and Management Co trades at $2.87 (market cap $422.94M), while TG Therapeutics Inc trades at $56.44 (market cap $8.89B). The key difference: TG Therapeutics Inc is far larger — about 21× Apartment Investment and Management Co's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | TGTX | |
|---|---|---|
Market Cap | $422.94M | $8.89B |
Sector | Real Estate | Health |
52-Week High | $8.76 | $58.06 |
52-Week Low | $2.87 | $26.39 |
Enterprise Value | $669.06M | $9.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.94, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported a net income of $554.01M for 2025, driven by a significant tax benefit, though revenue declined to $138.49M. Analyst consensus is mixed with 1 Buy and 2 Hold ratings. A $1.30 per share liquidating distribution is scheduled for June 2026, reflecting corporate restructuring efforts.
Outlook is cautious due to volatile earnings history and declining revenue, but the high net income margin and planned distribution offer some investor appeal. Key risks include inconsistent operational performance and high leverage, while institutional sentiment remains neutral pending clearer growth catalysts.
TGTX trades at $55.47, up 4.05% today, with a bullish technical signal from moving averages and strong fundamental profitability. Revenue grew to $616.29M in 2025 with a net income margin of 65.95%, though recent quarterly EPS missed expectations. Positive news includes a new Phase II study for Briumvi in schizophrenia and strong sales momentum.
Outlook is positive driven by Briumvi's expansion, but risks include clinical trial outcomes and earnings volatility. Analysts are bullish with 84.6% buy ratings. The stock's high valuation multiples warrant monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
